hAECs

PreclinicalBiologic

TThe Second Affiliated Hospital of Chongqing Medical University

hAECs is one of 10 biologic programs targeting Hematopoietic Stem Cell Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematopoietic Stem Cell TransplantationUnknown status

Ovarian InsufficiencyUnknown status

Hematopoietic Stem Cell TransplantationPreclinical

Unknown status

Ovarian InsufficiencyPreclinical

Unknown status

Competition

Competitive Landscape

10 competitors in Hematopoietic Stem Cell Transplantation

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Phase 3

1 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 3

Cyclophosphamide IV

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 4

Interleukin 2

EEssen Biotech

Phase 1

1 5

IFN-γ Positive Selected T-Cells

UUniversity Hospital, Basel, Switzerland

Phase 2

1 6

Dose Extension

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 1

1 7

hAECs

TThe Second Affiliated Hospital of Chongqing Medical University

Preclinical

1 8

Piperacillin-Tazobactam Combination Product

TThe University of Queensland

Preclinical

1 9

Hematopoietic Stem Cell

TTalaris Therapeutics Inc.

Preclinical

2 10

Baracle Tab.

SSeoul St. Mary's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Unknown status·PPeking University People's Hospital·N/A·NCT03764228·27 enrolled

Ovarian Insufficiency1 trial

Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT03207412·20 enrolled

Unspecified1 trial

Human Amniotic Epithelial Cells for Asherman's Syndrome

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 1·NCT03223454·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for hAECs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hAECs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hAECs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Second Affiliated Hospital of Chongqing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: TThe Second Affiliated Hospital of Chongqing Medical University

hAECs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

Ovarian Insufficiency1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News